Clinical Trials Logo

Clinical Trial Summary

This study will provide insights on the infusion parameters, dosing, and experience of participants transitioning to CUVITRU in a real-world setting.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03716700
Study type Observational
Source Takeda
Contact
Status Completed
Phase
Start date September 24, 2018
Completion date July 23, 2020

See also
  Status Clinical Trial Phase
Completed NCT03277313 - Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects Phase 3
Active, not recruiting NCT05513586 - A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants Phase 3
Recruiting NCT05986734 - Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
Completed NCT00546871 - Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects Phase 2/Phase 3
Recruiting NCT05755035 - A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases Phase 2/Phase 3
Completed NCT02593188 - Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
Completed NCT03116347 - Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects Phase 4
Completed NCT00157079 - Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Phase 3
Completed NCT01412385 - Immune Globulin Subcutaenous (Human), 20% Phase 2/Phase 3
Completed NCT00161993 - Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) Phase 2
Completed NCT01175213 - Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID Phase 3
Completed NCT01218438 - Phase 2/3 Study of IGSC, 20% in PIDD Phase 2/Phase 3
Completed NCT05150340 - A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) Phase 3
Not yet recruiting NCT06076642 - A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases Phase 3
Completed NCT00782106 - Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously Phase 1/Phase 2
Completed NCT01485796 - Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD Phase 2/Phase 3
Recruiting NCT06150534 - At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
Completed NCT00814320 - Gammagard Liquid and rHuPH20 in PID Phase 3
Completed NCT04346108 - A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) Phase 3